Analystreport

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) is now covered by analysts at B. Riley. They set a "buy" rating and a $11.50 price target on the stock.

IMPRIMIS PHARMACEUTICALS  (IMMY) 
Last imprimis pharmaceuticals earnings: 5/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: imprimisrx.com